1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends

Analysis of the Global Biosimilars Market

  • January 2014
  • 380 pages
  • Frost & Sullivan
Report ID: 1979537


Table of Contents

Impending Patent Expiries and Next-generation Biosimilars Pipeline Provide Impetus for Growth

Patent expirations of blockbuster biologics and a promising pipeline of biosimilars present positive opportunities for the global market. The research service provides analysis on regional market penetration and market dynamics. This study also provides a market overview, market engineering measurements, revenue forecasts, competitive analysis, and key trends for the biosimilars market and its segments. Regional analysis includes The United States, European countries such as the United Kingdom, Germany, France, Italy, Spain, Benelux, and Scandinavia as well as Asia-Pacific and Latin America. The study period is 2009–2019, with 2012 as the base year.


•The information contained in this research service was derived from a variety of relevant primary and secondary information sources.
•Primary interviews were conducted with industry participants in positions such as chairman and chief executive officer (CEO), director of investor relations, director of business development, chief business officer, media relations, and international key opinion leaders (KOL).
•Secondary data sources include government and public health organisation websites, the World Health Organization (WHO), European Medicines Agency (EMA), the US Food and Drug Administration (FDA) publications (annual reports, US Securities and Exchange Commission (SEC) filings, investor presentations, earnings transcripts, and press releases), government public sources, pharmaceutical industry databases, and published articles in scientific and medical journals.
•For the United States, Europe, and Latin America (LATAM), revenue forecasting is performed using a robust, data-driven, bottom-up approach. Marketed drugs, patent expiries, and potential new entrants in phase 3 of development and beyond are individually forecasted, and aggregate figures are provided. For the Asia-Pacific (APAC) region, forecasting is performed using a top-down model.

Key Findings

•The global biosimilars market will continue to grow from $X million in 2012 to approximately $X million in 2019, at a compound annual growth rate (CAGR) of X%.
•The biosimilars market is a growth market. The period from 2013 to 2015 is considered a time of significance for higher growth, with new products and segments adding up during this time period. Regulatory guidelines have been drafted by the EMA for erythropoietins (EPO), granulocyte colony stimulating factors (G-CSF), human growth hormone (HGH), and monoclonal antibodies (mAbs). The United States, India, and other regions have also drafted guidelines as the pathways are gradually becoming clear.
•The European market seems favourable due to increasing pressure to control the spiralling costs of healthcare. Biosimilar mAbs are thus expected to experience a positive trend in the region.
•The US market is underpenetrated, and a huge opportunity awaits biosimilar manufacturers.
•The Russian government plans to promote the country’s domestic biosimilars industry through subsidies and contracts for companies actively developing biosimilars.
•Several regional governments are actively promoting the growth of biosimilars. For example, the South Korean government is striving to make its country a global market leader, with the goal of attaining a global market share of X% by 2020 and with provisions of both financial and institutional support for those involved.
•Partnerships and alliances are the major focus of firms entering the biosimilars market, and there have been some notable deals between generic participants and biotech firms. Examples include generics giant Teva and a biologicals firm Cephalon, Indian generics manufacturer Lupin Pharmaceuticals and Australian biotech Neuclone, and German STADA Arzneimittel’s mAbs deal with Hungary-based Gedeon Richter.
•Non-pharma participants have made their entry into biosimilars through partnerships. For example, Japanese digital camera maker Fujifilm is developing biosimilars with the biotech firm Kyowa Hakko Kirin, and Korean electronics giant Samsung struck biosimilar deals with contract research organisation (CRO) Quintiles and, more recently, with the US biotech Biogen Idec.

Scope and Segmentation

Geographic Coverage: Global
Study Period: 2009–2019
Base Year: 2012
Forecast Period: 2013–2019
Monetary Unit: US Dollars

This report covers the following geographic markets:
•The United States
•European countries such as the United Kingdom, Germany, France, Italy, and Spain
oThe Benelux region: Belgium, Netherlands, and Luxembourg
oThe Scandinavian region: Denmark, Norway, and Sweden
•APAC: India, China, South Korea, Japan, and Australia
•LATAM: Brazil, Mexico, and Argentina

Key Questions This Study Will Answer

What is the current scenario of the global biosimilars market, and how far will it go?
What are the key factors driving the market, and what are the barriers that need to be resolved?
Which are the key market segments to look out for, and what are the key trends and regulatory aspects?
Who are the key market participants involved, and where do they stand?
What are the factors affecting the biosimilars market in different regions of Europe, and how will these factors affect the market in the future?
What is the future biosimilars market scenario, and what should market participants do to succeed?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Amrita helps you find the right report:


The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

OpportunityAnalyzer: Growth Hormone Deficiency - Opportunity Analysis and Forecasts to 2026

  • $ 10995
  • Industry report
  • May 2017
  • by GlobalData

OpportunityAnalyzer: Growth Hormone Deficiency - Opportunity Analysis and Forecasts to 2026 Summary Growth hormone deficiency (GHD) is a rare endocrine disorder characterized by inadequate secretion of ...

Erythropoietin (EPO) Drugs Market Analysis By Drug Class (Biologics, Biosimilars), By Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), By Application, And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • May 2017
  • by Grand View Research

The global erythropoietin (EPO) drugs market is expected to reach USD 17.4 billion by 2025, according to a new report by Grand View Research, Inc. Rising incidence of chronic diseases such as CKD and cance ...

Global Biosimilars Market

  • $ 4250
  • Industry report
  • July 2017
  • by Mordor Intelligence LLP

The global biosimilar market was estimated to be USD XX million in 2016 and is expected to reach USD XX million by 2021, witnessing a CAGR of XX% during the forecast period. Biosimilar is a biological ...


Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.